OKYO CEO and CSO to Present and Leadership Team to Participate at Upcoming Scientific Conferences in May

Summary by AI BETAClose X

OKYO Pharma Limited announced that its CEO will present at Eyecelerator on May 1, 2026, and its Chief Scientific Officer will present at the ARVO Annual Meeting on May 5, 2026, discussing positive Phase 2 data for urcosimod in treating neuropathic corneal pain (NCP). Urcosimod, a novel therapy for NCP, has shown clinically meaningful pain reduction and quality-of-life improvements in patients, with a larger 150-patient Phase 2b/3 study planned for initiation in the first half of the year. The company is developing urcosimod for inflammatory eye diseases and NCP, an area with currently no FDA-approved therapies.

Disclaimer*

UK 100

Latest directors dealings